These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32114513)

  • 1. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study.
    Chase D; Huang HQ; Monk BJ; Ramondetta LM; Penson RT; Gil K; Landrum LM; Leitao M; Oaknin A; Huh WK; Pulaski HL; Robison K; Guntupalli SR; Richardson D; Salani R; Sill MW; Wenzel LB; Tewari KS
    Int J Gynecol Cancer; 2020 May; 30(5):596-601. PubMed ID: 32114513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
    Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
    Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved survival with bevacizumab in advanced cervical cancer.
    Tewari KS; Sill MW; Long HJ; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
    N Engl J Med; 2014 Feb; 370(8):734-43. PubMed ID: 24552320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
    Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
    Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.
    Zighelboim I; Wright JD; Gao F; Case AS; Massad LS; Mutch DG; Powell MA; Thaker PH; Eisenhauer EL; Cohn DE; Valea FA; Alvarez Secord A; Lippmann LT; Dehdashti F; Rader JS
    Gynecol Oncol; 2013 Jul; 130(1):64-8. PubMed ID: 23591400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
    Tewari KS; Sill MW; Birrer MJ; Penson RT; Huang H; Moore DH; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
    Gynecol Oncol; 2023 Apr; 171():141-150. PubMed ID: 36898292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.
    Tewari KS; Sill MW; Monk BJ; Penson RT; Long HJ; Poveda A; Landrum LM; Leitao MM; Brown J; Reid TJ; Michael HE; Moore DH
    Clin Cancer Res; 2015 Dec; 21(24):5480-7. PubMed ID: 26672085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
    Krill LS; Tewari KS
    Expert Opin Pharmacother; 2015 Apr; 16(5):675-83. PubMed ID: 25643984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
    Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
    Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study.
    McQuellon RP; Thaler HT; Cella D; Moore DH
    Gynecol Oncol; 2006 May; 101(2):296-304. PubMed ID: 16376417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.
    Monk BJ; Huang HQ; Cella D; Long HJ;
    J Clin Oncol; 2005 Jul; 23(21):4617-25. PubMed ID: 15911864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.
    Cella D; Huang HQ; Monk BJ; Wenzel L; Benda J; McMeekin DS; Cohn D; Ramondetta L; Boardman CH
    Gynecol Oncol; 2010 Dec; 119(3):531-7. PubMed ID: 20837359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study.
    Chu G; Liu X; Yu W; Chen M; Dong L
    BMC Cancer; 2021 Feb; 21(1):133. PubMed ID: 33549065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer.
    Suzuki K; Nagao S; Shibutani T; Yamamoto K; Jimi T; Yano H; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
    Gynecol Oncol; 2019 Sep; 154(3):554-557. PubMed ID: 31285082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
    Redondo A; Colombo N; McCormack M; Dreosti L; Nogueira-Rodrigues A; Scambia G; Lorusso D; Joly F; Schenker M; Ruff P; Estevez-Diz M; Irahara N; Donica M; Gonzalez-Martín A
    Gynecol Oncol; 2020 Oct; 159(1):142-149. PubMed ID: 32763109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
    Grau JF; Farinas-Madrid L; Oaknin A
    Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
    Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J
    Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
    Lee JY; Park JY; Park SY; Lee JW; Kim JW; Kim YB; Jeong DH; Lee KB; Kim TH; Lee IH; Choi MC; Kim KH; Kim YM; Lee YJ; Kang S; ; Pujade-Lauraine E
    Gynecol Oncol; 2019 Jan; 152(1):61-67. PubMed ID: 30409490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.